Abstract:Copyright © 2021 Massachusetts Medical Society. Pulmonary hypertension is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive rise in the pulmonary vascular load, leading to hypertrophy and remodeling of the right ventricle. Death results from right ventricular failure if pulmonary hypertension is left untreated. Pulmonary hypertension is currently defined hemodynamically by a mean pulmonary arterial pressure of higher than 20 mm Hg at rest, as measured by right heart catheterization.1 Precapillary pulmonary hypertension due to pulmonary vascular disease is further defined by an elevation in pulmonary vascular resistance of at least 3 Wood units (WU), in contrast to isolated postcapillary pulmonary hypertension, in which the pulmonary vascular resistance is less than 3 WU and the elevation in the mean pulmonary arterial pressure is due to elevated filling pressures on the left side of the heart. The several forms of pulmonary hypertension are categorized into five clinical groups (Fig. 1). This review focuses on the relatively rare form of pulmonary arterial hypertension (group 1). Immense progress has been achieved in gaining an understanding of the mechanisms, natural history, and genetic features of pulmonary arterial hypertension and in establishing targeted therapy. A full appreciation of the pathophysiology of the syndrome is important, since the diagnosis requires a thorough clinical investigation to rule out other, more common forms of pulmonary hypertension, for which treatment of the underlying disease should be the primary goal. The first anatomical description of pulmonary hypertension is credited to von Romberg.2 However, it is the advent of human right heart catheterization, first performed by Forssmann on himself in 1929,3 that led to a flurry of physiological observations on the heart and pulmonary circulation by Cournand and Richards in the 1940s. The three investigators received the Nobel Prize in Physiology or Medicine in 1956 for their seminal work. In his illuminating Nobel Lecture, Richards noted that, as a result of their collective work, ì many forms and degrees of failure were defined, and their responses to treatment measured.î 4 In 1951, Dresdale, a disciple of Cournand and Richards, and colleagues presented the first case series of patients with pulmonary hypertension of unknown cause, defined as ì primary pulmonary hypertension.î 5 Greater awareness of the disease developed in the 1960s, after an epidemic of primary pulmonary hypertension that was associated with the use of the appetite suppressant aminorex.6 This prompted the World Health Organization to convene a first meeting of pulmonary hypertension experts in 1973, to standardize the clinical and pathological nomenclature of primary pulmonary hypertension, the first attempt at an organized classification.7 The first and second meetings about pulmonary hypertension were separated by 25 years, but thereafter the World Symposium on Pulmonary Hypertension (WSPH) was convened every 5 years. The meetings brought further refinement to the classification of pulmonary hypertension, with five distinct groups Darren B. Taichman, M.D., Ph.D., Editor

The Management of Mild Pulmonary Hypertension in Clinical Practice

Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer

Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications

Definition, classification and diagnosis of pulmonary hypertension

Haemodynamic definitions and updated clinical classification of pulmonary hypertension

Diagnosis and Management of Pulmonary Hypertension: New Insights

PULMONARY hypertension.

Current Progression in Diagnosis and Treatment of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease

Pulmonary Hypertension: A Contemporary Review

Management of pulmonary hypertension in special conditions

New diagnostic criteria and current issues for pulmonary hypertension

Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease

Pulmonary Arterial Hypertension.

[Impact of the 2022 ESC/ERS revised hemodynamic definition on the diagnosis of pulmonary hypertension]

Pharmacological Update and Emerging Treatments of Pulmonary Hypertension

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

A review regarding the article `Right heart catheterization in idiopathic pulmonary hypertension: An all-inclusive necessity'

Updated Perspectives on Pulmonary Hypertension in COPD

Impact of new definition on the prognosis of patients with pulmonary hypertension compared to classic definition

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

New criteria for diagnosis of pulmonary arterial hypertension: pros and cons